Durvalumab With Chemotherapy Shows Long-Term Overall Survival at 3 Years
Updated results from the TOPAZ-1 phase 3 trial showed that durvalumab (Imfinzi; AstraZeneca) combined with the standard-of-care chemotherapy demonstrated clinically meaningful long-term overall survival (OS) at 3 years for individuals with advanced biliary …